Bastian Schilling

49PUBLICATIONS
174CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Chemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (49)

|Aug 18, 2026
Immunotherapy of malignant melanoma using T cell-activating microbeads.

|Feb 20, 2026
Melanoma of unknown primary shows an oncogenic pattern and clinical course of sun-exposed melanoma.

Georg Lodde, Jonida Dollani, Wolfgang Galetzka

|Jan 25, 2026
Neoadjuvant therapy in skin cancer: current evidence and future perspectives.

Lea Daniello, Johannes Kleemann, Bastian Schilling

|Jan 20, 2026
Perioperative Pembrolizumab in Locally Advanced Melanoma: A Real-world Single-centre Retrospective Study.

Simon Goller, Tassilo Dege, Patrick Schummer

|Sep 24, 2025
Infliximab is a safe and effective treatment in steroid-refractory immune-related hepatitis.

Kim Nikola Oliva, Lisa Arnold, Lucie Heinzerling

|Sep 04, 2025
Breaking primary checkpoint inhibitor resistance with intermittent alkylating chemotherapy in patients with metastatic melanoma: results of a multicentre phase II trial.

Sebastian Haferkamp, Bastian Schilling, Carola Berking

Pageof 9

Frequent Collaborators

14 joint publications

Dirk Schadendorf

8 joint publications

Markus V Heppt

7 joint publications

Jochen Utikal

6 joint publications

Selma Ugurel